Prevention and treatment of acute GvHD.
GvHD remains a source of significant morbidity and mortality in the setting of allogeneic haematopoietic SCT. Improving outcomes in stem cell transplant recipients requires additional therapeutic modalities for GvHD, especially for patients who fail to respond to initial therapy with steroids. Moreover, while the absence of acute GvHD (aGvHD) is associated with a higher risk of relapse of the underlying malignant disease, severe aGvHD usually induces the occurrence of life-threatening complications such as severe infections. This article summarizes the current state of aGvHD prophylaxis and treatment.
Messina
C
C
Bone Marrow Unit, Paediatric Onco-Haematology Clinic, University of Padova, Padova, Italy. chiara.messina@unipd.it
Faraci
M
M
de Fazio
V
V
Dini
G
G
Calò
M P
MP
Calore
E
E
D002648:Child; D006086:Graft vs Host Disease / Q000145:classification / Q000188:drug therapy* / Q000517:prevention & control*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D013256:Steroids / Q000627:therapeutic use; D050378:T-Lymphocytes, Regulatory; D016559:Tacrolimus / Q000627:therapeutic use; D014184:Transplantation, Homologous; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D007166:Immunosuppressive Agents; D013256:Steroids; D014409:Tumor Necrosis Factor-alpha; D016559:Tacrolimus